Genmab — Remuneration Information 2015

Dec 10, 2015

Company Announcement

Copenhagen, Denmark; December 10, 2015 – Genmab A/S (Nasdaq Copenhagen: GEN)
announced today that at a board meeting the board decided to grant 23,145
restricted stock units to members of the board of directors and management and
101,750 warrants to employees of the company as well as the company’s
subsidiaries.

Each restricted stock unit provides the owner with a right and obligation to
receive one share in Genmab A/S of nominally DKK 1. The fair value of each
restricted stock unit is equal to the closing market price on the date of grant
of one Genmab A/S share, DKK 939.50.

The restricted stock units will vest on the first banking day of the month
following a period of three years from the date of grant. Furthermore, the
restricted stock units are subject to vesting conditions set out in the
restricted stock unit program adopted by the board of directors in accordance
with the general guidelines for incentive-based remuneration adopted by the
shareholders at the annual general meeting. Information concerning Genmab’s
restricted stock unit program can be found on www.genmab.com under Investors >
Stock information > Restricted stock units.

The exercise price for each warrant is DKK 939.50. Each warrant entitles the
owner to subscribe one share of nominally DKK 1. On the basis of an exercise
price of DKK 939.50 and by application of the Black-Scholes formula, the
average value of each warrant can be calculated as DKK 307.98 based on an
interest rate of 0.225 % and the historical volatility of Genmab A/S shares
calculated at 40.23%.

The warrants vest in blocks of 25% one, two, three and four years after the
grant date, and all warrants expire at the seventh anniversary of the grant
date. The new warrants were granted pursuant to the warrant plan adopted by the
board on April 25, 2012. Information concerning Genmab’s warrant schemes can be
found on www.genmab.com under Investors > Stock information > Warrants.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia
indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated
or double refractory multiple myeloma. Daratumumab is in clinical development
for additional multiple myeloma indications and for non-Hodgkin’s lymphoma.
Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody
technologies - the DuoBody® platform for generation of bispecific antibodies,
and the HexaBody® platform which creates effector function enhanced antibodies.
The company intends to leverage these technologies to create opportunities for
full or co-ownership of future products. Genmab has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX™ is a trademark of Janssen Biotech, Inc.

Company Announcement no. 63
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark